A Phase 3 interventional study of Teduglutide in Short Bowel Syndrome, sponsored by Shire. Completed at 6 sites in Japan. Per ClinicalTrials.gov, last updated 2022-05-24.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing teduglutide in Short Bowel Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. teduglutide · Short Bowel Syndrome.
Among the 20 studies testing teduglutide in Short Bowel Syndrome, this one is the 17th largest by enrollment, is one of 2 that started in 2017, is one of 16 in phase 3, and was the 13th registered.
159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.
Browse Short Bowel Syndrome studies →1 of the 20 studies testing teduglutide in Short Bowel Syndrome is open now, in 1 country. Recruiting first, the newest first:
Meyer Children's Hospital IRCCS · Sites in Italy
Ages 4 mo–17 yrs
By country, each count listing its studies:
teduglutide: first FDA approval 2012 (GATTEX KIT), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2017.
This study's enrollment of 9 is below the median of 21 across 108 interventional studies indexed under Short Bowel Syndrome.
Median enrollment 20 across the 20 interventional studies. Of the 18 that completed or were terminated, 16 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 20 have an industry lead sponsor. The 6 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
26 studies in Short Bowel Syndrome by Takeda: 1 open now, 3 under way, 1 of them phase 3. Of 23 finished, 16 (70%) have results posted.
Among the 26 studies in Short Bowel Syndrome by Takeda, this one is the 16th largest by enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2017, is one of 17 in phase 3, and was the 14th registered.
Takeda’s Short Bowel Syndrome studies by the year they started, since 2004.
1 of the studies testing teduglutide in Short Bowel Syndrome that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06973304Phase 3TakedaA Study of Teduglutide in Chinese Adults With Short Bowel Syndrome | 2027-02-10 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing teduglutide in Short Bowel Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 26 in Short Bowel Syndrome:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical study is to evaluate the long-term safety and tolerability of teduglutide treatment in Japanese pediatric participants with short bowel syndrome (SBS) who completed Study SHP633-302 (NCT02980666).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
There are no exclusion criteria for this study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24-week intervals. If a participant deteriorates during a follow-up period, the participant may be evaluated immediately for additional teduglutide treatment (24-week interval) until teduglutide is commercially available for each participant, the participant's participation in this study is discontinued, or the study is discontinued.
Drug: Teduglutide
Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An Adverse Event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs were defined as any AEs whose onset occurred, severity worsened or intensity increased after receiving the investigational product (IP) in the core study (SHP633-302 \[NCT02980666\]) or this extension study. Number of participants with TEAEs were reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: From Baseline up to follow-up (up to 50 months)
Number of Participants With Clinically Significant Abnormalities in Vital Signs
Vital sign assessments included pulse rate, blood pressure (systolic and diastolic blood pressure) and body temperature. Number of participants with clinically significant abnormalities in vital signs which were deemed clinically significant by the investigator were reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: From Baseline up to follow-up (up to 50 months)
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters
Clinical laboratory parameters included biochemistry, hematology and urinalysis. Number of participants with clinically significant abnormalities in laboratory parameters which were deemed clinically significant by the investigator were reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: From Baseline up to follow-up (up to 50 months)
Percent Change From Baseline in Average Total Urine Output at End of Treatment (EOT) of Last Cycle During Teduglutide Treatment
Average total urine output was recorded over a 48-hour period of parental support (PS) stability before every scheduled site visit and within 1 week of implementing any PS adjustment. The Average daily urine output milliliter per kilogram per day (mL/kg/day) was calculated as: (Total urine output over 48 hours / 2) / body weight (kilogram \[kg\]) where total urine output was calculated as the sum of the urine output in milliliter (mL) and the urine-only diaper weights in gram (g) (1g = 1mL) for the participant collected on the output diary form of electronic case report from (eCRF). Percent change from baseline in average total urine output at EOT of last cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of last cycle (up to Month 45) (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Percent Change From Baseline in Average Number of Stools Per Day at EOT of Last Cycle During Teduglutide Treatment
Fecal output was recorded over a 48-hour period of PS stability before every scheduled site visit and within 1 week of implementing any PS adjustment. The average daily fecal output was summarized by the average number of stools per day. The average number of stools per day was calculated as (sum of the daily data in a 48-hour period/2). Percent change from baseline in average number of stools per day at EOT of last cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of last cycle (up to Month 45) (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Percent Change From Baseline in Average Stool/Mixed Stool Diaper Weight at EOT of Last Cycle During Teduglutide Treatment
Fecal output was recorded over a 48-hour period of PS stability before every scheduled site visit and within 1 week of implementing any PS adjustment. The average daily fecal output was summarized by the average stool/mixed stool diaper weight (gram per kilogram per day \[g/kg/day\]). The body weight was used to calculate the daily stool/mixed stool diaper weight (g/kg/day). Percent change from baseline in average stool/mixed stool diaper weight at EOT of last cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of last cycle (up to Month 45) (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Percent Change From Baseline in Average Total Ostomy Output at EOT of Last Cycle During Teduglutide Treatment
Fecal output was recorded over a 48-hour period of PS stability before every scheduled site visit and within 1 week of implementing any PS adjustment. The body weight was used to calculate the average total ostomy output per day (mL/kg/day) using a formula analogous to that used to calculate the average daily urine output. Percent change from baseline in average total ostomy output at EOT of last cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of last cycle (up to Month 45) (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Percent Change From Baseline in Average Bristol Stool Form Score at EOT of Last Cycle During Teduglutide Treatment
Fecal output was recorded over a 48-hour period of PS stability before every scheduled site visit and within 1 week of implementing any PS adjustment. The average daily fecal output was summarized the average typical stool form score using Bristol Stool Form Scale. The average typical stool form score was calculated as (sum of the daily data in a 48-hour period / 2). Typical Stool Form based on Bristol Stool Form Scale: 1 - Separate hard lumps, hard to pass, 2 - Sausage-shaped, but lumpy, 3 - Like a sausage but with cracks on the surface, 4- Like a sausage or snake, smooth and soft, 5- Soft blobs with clear-cut edges, 6- Fluffy pieces with ragged edges, a mushy stool, 7- Watery, no solid pieces. Entirely liquid. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]). A negative change from baseline indicates improvement.
Time frame: Baseline, EOT of last cycle (up to Month 45) (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Number of Participants With Anti-drug Antibodies (ADAs) (Including Neutralizing Antibodies) at EOT of Last Cycle During Teduglutide Treatment
Number of participants with ADAs (including NAbs) to teduglutide were used to summarize the presence of antibodies. The participants who tested positive only for ADAs (including NAbs) were reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of last cycle (up to Month 45) (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Number of Participants With Clinically Significant Changes in Gastrointestinal (GI) Specific Testing
GI specific testing included colonoscopy or sigmoidoscopy, abdominal ultrasound, fecal occult blood testing, upper GI series with small bowel follow-through (UGI/SBFT). Number of participants with clinically significant changes findings in gastrointestinal specific testing were reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of last cycle (up to Month 45) (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Change From Baseline in Body Weight For Age Z-Score at EOT of Last Cycle During Teduglutide Treatment
Body weight was measured using Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in body weight for age Z-Score at EOT of last cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of last cycle (up to Month 45) (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Change From Baseline in Height For Age Z-Score at EOT of Cycle 1 During Teduglutide Treatment
Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-Score at EOT of cycle 1 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of Cycle 1 (up to 24 Weeks)
Change From Baseline in Height For Age Z-Score at EOT of Cycle 2 During Teduglutide Treatment
Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at EOT of Cycle 2 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of Cycle 2 (up to 48 weeks)
Change From Baseline in Height For Age Z-Score at EOT of Cycle 3 During Teduglutide Treatment
Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at EOT of Cycle 3 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of Cycle 3 (up to 72 weeks)
Change From Baseline in Height For Age Z-Score at EOT of Cycle 4 During Teduglutide Treatment
Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at EOT of Cycle 4 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of Cycle 4 (up to 96 weeks)
Change From Baseline in Height For Age Z-Score at EOT of Cycle 5 During Teduglutide Treatment
Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at EOT of Cycle 5 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of Cycle 5 (up to 120 weeks)
Change From Baseline in Height For Age Z-Score at EOT of Cycle 6 During Teduglutide Treatment
Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at EOT of Cycle 6 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of Cycle 6 (up to 144 weeks)
Change From Baseline in Height For Age Z-Score at EOT of Cycle 7 During Teduglutide Treatment
Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at EOT of Cycle 7 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of Cycle 7 (up to 168 weeks)
Change From Baseline in Height For Age Z-Score at EOT of Cycle 8 During Teduglutide Treatment
Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at EOT of Cycle 8 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of Cycle 8 (up to 192 weeks)
Change From Baseline in Height For Age Z-Score at EOT of Cycle 9 During Teduglutide Treatment
Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at EOT of Cycle 9 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of Cycle 9 (up to 196 weeks)
Change From Baseline in Head Circumference for Age Z-score at EOT of Cycle 1 During Teduglutide Treatment
Head circumference was measured using Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in head circumference for Age Z-score at EOT of Cycle 1 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of Cycle 1 (up to 24 weeks)
Change From Baseline in Head Circumference for Age Z-score at EOT of Cycle 2 During Teduglutide Treatment
Head circumference was measured using Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in head circumference for Age Z-score at EOT of Cycle 2 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of Cycle 2 (up to 48 weeks)
Change From Baseline in Head Circumference for Age Z-score at EOT of Cycle 3 During Teduglutide Treatment
Head circumference was measured using Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in head circumference for Age Z-score at EOT of Cycle 3 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of Cycle 3 (up to 72 weeks)
Change From Baseline in Head Circumference for Age Z-score at EOT of Cycle 4 During Teduglutide Treatment
Head circumference was measured using Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in head circumference for Age Z-score at EOT of Cycle 4 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of Cycle 4 (up to 76 weeks)
Change From Baseline in Body Mass Index (BMI) for Age Z-score at EOT of Cycle 1 During Teduglutide Treatment
BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 1 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of Cycle 1 (up to 24 weeks)
Change From Baseline in BMI for Age Z-score at EOT of Cycle 2 During Teduglutide Treatment
BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 2 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of Cycle 2 (up to 48 weeks)
Change From Baseline in BMI for Age Z-score at EOT of Cycle 3 During Teduglutide Treatment
BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 3 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of Cycle 3 (up to 72 weeks)
Change From Baseline in BMI for Age Z-score at EOT of Cycle 4 During Teduglutide Treatment
BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 4 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of Cycle 4 (up to 96 weeks)
Change From Baseline in BMI for Age Z-score at EOT of Cycle 5 During Teduglutide Treatment
BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 5 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of Cycle 5 (up to 120 weeks)
Change From Baseline in BMI for Age Z-score at EOT of Cycle 6 During Teduglutide Treatment
BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 6 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of Cycle 6 (up to 144 weeks)
Change From Baseline in BMI for Age Z-score at EOT of Cycle 7 During Teduglutide Treatment
BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 7 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of Cycle 7 (up to 168 weeks)
Change From Baseline in BMI for Age Z-score at EOT of Cycle 8 During Teduglutide Treatment
BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 8 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of Cycle 8 (up to 192 weeks)
Change From Baseline in BMI for Age Z-score at EOT of Cycle 9 During Teduglutide Treatment
BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 9 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of Cycle 9 (up to 196 weeks)
Number of Participants Who Achieved At Least 20 Percent (%) Reduction From Baseline in Participants Diary Parenteral Support (PS) Volume at EOT of Each Cycle During Teduglutide Treatment
PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume during the treatment period. Percent reduction in weight-normalized diary PS values from baseline was calculated using the formula: % reduction in PS value at the visit = (\[average daily value at the scheduled visit - average daily value at baseline of the core study (SHP633-302 \[NCT02980666\]) / average daily value at baseline of the core study (SHP633-302 \[NCT02980666\])) \*100. Number of participants who achieved at least 20% reduction from baseline in participants diary PS volume at EOT of each cycle during teduglutide treatment were reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Number of Participants Who Achieved At Least 20 Percent (%) Reduction From Baseline in Investigator Prescribed PS Volume at EOT of Each Cycle During Teduglutide Treatment
PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume during the treatment period. Percent reduction in weight-normalized prescribed PS values from baseline was calculated using the formula: % reduction in PS value at the visit =(\[average daily value at the scheduled visit - average daily value at baseline of the core study (SHP633-302 \[NCT02980666\]) / average daily value at baseline of the core study (SHP633-302 \[NCT02980666\])) \*100. Number of participants who achieved at least 20% reduction from baseline in Investigator prescribed PS volume at EOT of each cycle during teduglutide treatment were reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Change From Baseline in Participant Diary PS Volume at EOT of Each Cycle During Teduglutide Treatment
PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume during the treatment period. Change from baseline in participants diary PS volume at EOT of each cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Percent Change From Baseline in Participant Diary PS Volume at EOT of Each Cycle During Teduglutide Treatment
PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume during the treatment period. Percent change from baseline in participants diary PS volume at EOT of each cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Change From Baseline in Investigator Prescribed PS Volume at EOT of Each Cycle During Teduglutide Treatment
PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume during the treatment period. Change from baseline in investigator prescribed PS volume at EOT of each cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Percent Change From Baseline in Investigator Prescribed PS Volume at EOT of Each Cycle During Teduglutide Treatment
PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume during the treatment period. Percent change from baseline in investigator prescribed PS volume at EOT of each cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Number of Participants Who Achieved Enteral Autonomy PS Volume at EOT of Each Cycle During Teduglutide Treatment
Enteral autonomy (completely weaned off PS) was defined as the first visit where there is no use of PS for the 7 days prior to the visit and there is no prescribed PS at that visit, and the participants remains off PS for the remainder of the treatment period of that cycle. Number of participants who achieved enteral autonomy off PS volume at EOT of each cycle during teduglutide treatment were reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Change From Baseline in Days Per Week of Diary PS Usage at EOT of Each Cycle During Teduglutide Treatment
Days per week of diary PS was calculated as: Days per week of actual PS = (number of days with non-zero values for PS volume within the 7 days prior to the visit / number of days for which any PS intake data was recorded within the 7 days prior to the visit) \* 7. Change from baseline in days per week of diary PS usage at EOT of each cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
Change From Baseline in Days Per Week of Prescribed PS Usage at EOT of Each Cycle During Teduglutide Treatment
Change from baseline in days per week of prescribed PS usage at EOT of each cycle during teduglutide treatment was reported. Days per week of diary PS was calculated as: Days per week of actual PS = (number of days with non-zero values for PS volume within the 7 days prior to the visit / number of days for which any PS intake data was recorded within the 7 days prior to the visit) \* 7. Change from baseline in days Per week of prescribed PS usage at EOT of each cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
Time frame: Baseline, EOT of each cycle 1, 2, 3, 4, 5, 6, 7, 8 and 9 (Each Cycle 1 to 8 = 24 weeks, and Cycle 9 = 4 weeks)
The study was conducted at 6 centers in Japan from 23 August 2017 (first participant first visit) and 02 November 2021 (last participant last visit).
| Milestone | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Started | 7 | 2 |
| Completed | 7 | 1 |
| Not completed | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
An Adverse Event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs were defined as any AEs whose onset occurred, severity worsened or intensity increased after receiving the investigational product (IP) in the core study (SHP633-302 \[NCT02980666\]) or this extension study. Number of participants with TEAEs were reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Participants | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 7 | 2 |
Vital sign assessments included pulse rate, blood pressure (systolic and diastolic blood pressure) and body temperature. Number of participants with clinically significant abnormalities in vital signs which were deemed clinically significant by the investigator were reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Participants | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Number of Participants With Clinically Significant Abnormalities in Vital Signs | 0 | 0 |
Clinical laboratory parameters included biochemistry, hematology and urinalysis. Number of participants with clinically significant abnormalities in laboratory parameters which were deemed clinically significant by the investigator were reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Participants | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Biochemistry | 5 | 1 |
| Hematology | 1 | 0 |
| Urinalysis. | 0 | 0 |
Average total urine output was recorded over a 48-hour period of parental support (PS) stability before every scheduled site visit and within 1 week of implementing any PS adjustment. The Average daily urine output milliliter per kilogram per day (mL/kg/day) was calculated as: (Total urine output over 48 hours / 2) / body weight (kilogram \[kg\]) where total urine output was calculated as the sum of the urine output in milliliter (mL) and the urine-only diaper weights in gram (g) (1g = 1mL) for the participant collected on the output diary form of electronic case report from (eCRF). Percent change from baseline in average total urine output at EOT of last cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Percent change | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Percent Change From Baseline in Average Total Urine Output at End of Treatment (EOT) of Last Cycle During Teduglutide Treatment | -37.228 ± 42.9396 | 146.881 ± 295.8061 |
Fecal output was recorded over a 48-hour period of PS stability before every scheduled site visit and within 1 week of implementing any PS adjustment. The average daily fecal output was summarized by the average number of stools per day. The average number of stools per day was calculated as (sum of the daily data in a 48-hour period/2). Percent change from baseline in average number of stools per day at EOT of last cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Percent change | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Percent Change From Baseline in Average Number of Stools Per Day at EOT of Last Cycle During Teduglutide Treatment | 24.37 ± 63.623 | 50.00 ± 0.000 |
Fecal output was recorded over a 48-hour period of PS stability before every scheduled site visit and within 1 week of implementing any PS adjustment. The average daily fecal output was summarized by the average stool/mixed stool diaper weight (gram per kilogram per day \[g/kg/day\]). The body weight was used to calculate the daily stool/mixed stool diaper weight (g/kg/day). Percent change from baseline in average stool/mixed stool diaper weight at EOT of last cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Percent change | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Percent Change From Baseline in Average Stool/Mixed Stool Diaper Weight at EOT of Last Cycle During Teduglutide Treatment | -12.678 ± NA | 206.017 ± 332.4580 |
Fecal output was recorded over a 48-hour period of PS stability before every scheduled site visit and within 1 week of implementing any PS adjustment. The body weight was used to calculate the average total ostomy output per day (mL/kg/day) using a formula analogous to that used to calculate the average daily urine output. Percent change from baseline in average total ostomy output at EOT of last cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Percent change | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Percent Change From Baseline in Average Total Ostomy Output at EOT of Last Cycle During Teduglutide Treatment | — | 3.143 ± 145.8659 |
Fecal output was recorded over a 48-hour period of PS stability before every scheduled site visit and within 1 week of implementing any PS adjustment. The average daily fecal output was summarized the average typical stool form score using Bristol Stool Form Scale. The average typical stool form score was calculated as (sum of the daily data in a 48-hour period / 2). Typical Stool Form based on Bristol Stool Form Scale: 1 - Separate hard lumps, hard to pass, 2 - Sausage-shaped, but lumpy, 3 - Like a sausage but with cracks on the surface, 4- Like a sausage or snake, smooth and soft, 5- Soft blobs with clear-cut edges, 6- Fluffy pieces with ragged edges, a mushy stool, 7- Watery, no solid pieces. Entirely liquid. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]). A negative change from baseline indicates improvement.
| Percent change | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Percent Change From Baseline in Average Bristol Stool Form Score at EOT of Last Cycle During Teduglutide Treatment | -7.51 ± 16.758 | 0.00 ± 0.000 |
Number of participants with ADAs (including NAbs) to teduglutide were used to summarize the presence of antibodies. The participants who tested positive only for ADAs (including NAbs) were reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Participants | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Positive ADA at EOT of the Last Cycle | 5 | 0 |
| Positive NAbs at EOT of the Last Cycle | 4 | — |
GI specific testing included colonoscopy or sigmoidoscopy, abdominal ultrasound, fecal occult blood testing, upper GI series with small bowel follow-through (UGI/SBFT). Number of participants with clinically significant changes findings in gastrointestinal specific testing were reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Participants | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Number of Participants With Clinically Significant Changes in Gastrointestinal (GI) Specific Testing | 0 | 0 |
Body weight was measured using Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in body weight for age Z-Score at EOT of last cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Z-score | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Change From Baseline in Body Weight For Age Z-Score at EOT of Last Cycle During Teduglutide Treatment | 0.229 ± 0.5636 | 3.982 ± 3.6363 |
Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-Score at EOT of cycle 1 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Z-score | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Change From Baseline in Height For Age Z-Score at EOT of Cycle 1 During Teduglutide Treatment | 0.002 ± 0.6049 | 1.376 ± 0.3363 |
Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at EOT of Cycle 2 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Z-score | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Change From Baseline in Height For Age Z-Score at EOT of Cycle 2 During Teduglutide Treatment | 0.152 ± 0.5181 | 3.114 ± NA |
Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at EOT of Cycle 3 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Z-score | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Change From Baseline in Height For Age Z-Score at EOT of Cycle 3 During Teduglutide Treatment | 0.098 ± 0.3467 | 3.554 ± NA |
Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at EOT of Cycle 4 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Z-Score | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Change From Baseline in Height For Age Z-Score at EOT of Cycle 4 During Teduglutide Treatment | 0.126 ± 0.2622 | 3.542 ± NA |
Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at EOT of Cycle 5 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Z-score | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Change From Baseline in Height For Age Z-Score at EOT of Cycle 5 During Teduglutide Treatment | 0.342 ± 0.1012 | — |
Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at EOT of Cycle 6 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Z-score | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Change From Baseline in Height For Age Z-Score at EOT of Cycle 6 During Teduglutide Treatment | 0.276 ± 0.2593 | — |
Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at EOT of Cycle 7 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Z-score | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Change From Baseline in Height For Age Z-Score at EOT of Cycle 7 During Teduglutide Treatment | 0.570 ± NA | — |
Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at EOT of Cycle 8 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Z-score | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Change From Baseline in Height For Age Z-Score at EOT of Cycle 8 During Teduglutide Treatment | 0.851 ± NA | — |
Height was measured using Age Z-Score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score at EOT of Cycle 9 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Z-score | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Change From Baseline in Height For Age Z-Score at EOT of Cycle 9 During Teduglutide Treatment | 0.477 ± NA | — |
Head circumference was measured using Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in head circumference for Age Z-score at EOT of Cycle 1 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Z-score | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Change From Baseline in Head Circumference for Age Z-score at EOT of Cycle 1 During Teduglutide Treatment | — | 2.400 ± 0.6472 |
Head circumference was measured using Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in head circumference for Age Z-score at EOT of Cycle 2 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Z-score | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Change From Baseline in Head Circumference for Age Z-score at EOT of Cycle 2 During Teduglutide Treatment | — | 1.431 ± NA |
Head circumference was measured using Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in head circumference for Age Z-score at EOT of Cycle 3 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Z-score | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Change From Baseline in Head Circumference for Age Z-score at EOT of Cycle 3 During Teduglutide Treatment | — | 2.080 ± NA |
Head circumference was measured using Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in head circumference for Age Z-score at EOT of Cycle 4 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Z-score | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Change From Baseline in Head Circumference for Age Z-score at EOT of Cycle 4 During Teduglutide Treatment | — | 2.055 ± NA |
BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 1 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Z-score | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Change From Baseline in Body Mass Index (BMI) for Age Z-score at EOT of Cycle 1 During Teduglutide Treatment | 0.090 ± 0.6642 | — |
BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 2 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Z-score | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Change From Baseline in BMI for Age Z-score at EOT of Cycle 2 During Teduglutide Treatment | 0.489 ± 0.8474 | — |
BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 3 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Z-score | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Change From Baseline in BMI for Age Z-score at EOT of Cycle 3 During Teduglutide Treatment | 0.409 ± 1.1688 | — |
BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 4 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Z-score | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Change From Baseline in BMI for Age Z-score at EOT of Cycle 4 During Teduglutide Treatment | 0.118 ± 0.8827 | — |
BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 5 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Z-score | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Change From Baseline in BMI for Age Z-score at EOT of Cycle 5 During Teduglutide Treatment | 0.070 ± 0.9770 | — |
BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 6 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Z-score | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Change From Baseline in BMI for Age Z-score at EOT of Cycle 6 During Teduglutide Treatment | 0.925 ± 0.2556 | — |
BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 7 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Z-score | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Change From Baseline in BMI for Age Z-score at EOT of Cycle 7 During Teduglutide Treatment | 0.839 ± NA | — |
BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 8 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Z-score | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Change From Baseline in BMI for Age Z-score at EOT of Cycle 8 During Teduglutide Treatment | 0.015 ± NA | — |
BMI Z-score was calculated by using the height and weight Age Z-score. A Z-score was the deviation of the value for an individual from the mean value of the reference population divided by the standard deviation for the reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts were used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for Age Z-score at EOT of Cycle 9 during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Z-score | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Change From Baseline in BMI for Age Z-score at EOT of Cycle 9 During Teduglutide Treatment | 0.480 ± NA | — |
PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume during the treatment period. Percent reduction in weight-normalized diary PS values from baseline was calculated using the formula: % reduction in PS value at the visit = (\[average daily value at the scheduled visit - average daily value at baseline of the core study (SHP633-302 \[NCT02980666\]) / average daily value at baseline of the core study (SHP633-302 \[NCT02980666\])) \*100. Number of participants who achieved at least 20% reduction from baseline in participants diary PS volume at EOT of each cycle during teduglutide treatment were reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Participants | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| At least 20% Reduction: At EOT of Cycle 1 | 4 | 1 |
| At least 20% Reduction: At EOT of Cycle 2 | 4 | 1 |
| At least 20% Reduction: At EOT of Cycle 3 | 6 | 1 |
| At least 20% Reduction: At EOT of Cycle 4 | 5 | 1 |
| At least 20% Reduction: At EOT of Cycle 5 | 3 | — |
| At least 20% Reduction: At EOT of Cycle 6 | 2 | — |
| At least 20% Reduction: At EOT of Cycle 7 | 1 | — |
| At least 20% Reduction: At EOT of Cycle 8 | 1 | — |
| At least 20% Reduction: At EOT of Cycle 9 | 1 | — |
PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume during the treatment period. Percent reduction in weight-normalized prescribed PS values from baseline was calculated using the formula: % reduction in PS value at the visit =(\[average daily value at the scheduled visit - average daily value at baseline of the core study (SHP633-302 \[NCT02980666\]) / average daily value at baseline of the core study (SHP633-302 \[NCT02980666\])) \*100. Number of participants who achieved at least 20% reduction from baseline in Investigator prescribed PS volume at EOT of each cycle during teduglutide treatment were reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Participants | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| At least 20% Reduction: At EOT of Cycle 1 | 5 | 1 |
| At least 20% Reduction: At EOT of Cycle 2 | 5 | 1 |
| At least 20% Reduction: At EOT of Cycle 3 | 6 | 1 |
| At least 20% Reduction: At EOT of Cycle 4 | 5 | 1 |
| At least 20% Reduction: At EOT of Cycle 5 | 3 | — |
| At least 20% Reduction: At EOT of Cycle 6 | 2 | — |
| At least 20% Reduction: At EOT of Cycle 7 | 1 | — |
| At least 20% Reduction: At EOT of Cycle 8 | 1 | — |
| At least 20% Reduction: At EOT of Cycle 9 | 1 | — |
PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume during the treatment period. Change from baseline in participants diary PS volume at EOT of each cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| mL/kg/day | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Change at EOT of Cycle 1 | -21.5 ± 11.83 | -31.9 ± 16.24 |
| Change at EOT of Cycle 2 | -25.5 ± 14.38 | -54.2 ± NA |
| Change at EOT of Cycle 3 | -32.1 ± 18.19 | -62.8 ± NA |
| Change at EOT of Cycle 4 | -37.2 ± 24.10 | -95.8 ± NA |
| Change at EOT of Cycle 5 | -54.8 ± 26.58 | — |
| Change at EOT of Cycle 6 | -63.8 ± 31.57 | — |
| Change at EOT of Cycle 7 | -93.8 ± NA | — |
| Change at EOT of Cycle 8 | -80.3 ± NA | — |
| Change at EOT of Cycle 9 | -79.1 ± NA | — |
PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume during the treatment period. Percent change from baseline in participants diary PS volume at EOT of each cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Percent change | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Percent change at EOT of Cycle 1 | -39.6 ± 34.86 | -32.5 ± 18.10 |
| Percent change at EOT of Cycle 2 | -44.3 ± 33.11 | -56.6 ± NA |
| Percent change at EOT of Cycle 3 | -52.8 ± 28.54 | -65.6 ± NA |
| Percent change at EOT of Cycle 4 | -62.9 ± 26.18 | -100.0 ± NA |
| Percent change at EOT of Cycle 5 | -73.9 ± 5.30 | — |
| Percent change at EOT of Cycle 6 | -75.7 ± 0.54 | — |
| Percent change at EOT of Cycle 7 | -82.9 ± NA | — |
| Percent change at EOT of Cycle 8 | -70.9 ± NA | — |
| Percent change at EOT of Cycle 9 | -69.8 ± NA | — |
PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume during the treatment period. Change from baseline in investigator prescribed PS volume at EOT of each cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| mL/kg/day | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Change at EOT of Cycle 1 | -20.9 ± 11.06 | -31.3 ± 26.77 |
| Change at EOT of Cycle 2 | -28.0 ± 13.51 | -60.6 ± NA |
| Change at EOT of Cycle 3 | -34.8 ± 21.13 | -67.5 ± NA |
| Change at EOT of Cycle 4 | -36.3 ± 23.52 | -98.7 ± NA |
| Change at EOT of Cycle 5 | -53.3 ± 26.24 | — |
| Change at EOT of Cycle 6 | -63.6 ± 32.10 | — |
| Change at EOT of Cycle 7 | -91.8 ± NA | — |
| Change at EOT of Cycle 8 | -77.3 ± NA | — |
| Change at EOT of Cycle 9 | -77.9 ± NA | — |
PS (parenteral nutrition or intravenous fluids) was considered for managing nutritional support in terms of volume during the treatment period. Percent change from baseline in investigator prescribed PS volume at EOT of each cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Percent change | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Percent change at EOT of Cycle 1 | -38.8 ± 35.19 | -32.1 ± 26.51 |
| Percent change at EOT of Cycle 2 | -46.9 ± 30.42 | -61.4 ± NA |
| Percent change at EOT of Cycle 3 | -55.4 ± 27.78 | -68.3 ± NA |
| Percent change at EOT of Cycle 4 | -62.5 ± 26.45 | -100.0 ± NA |
| Percent change at EOT of Cycle 5 | -73.3 ± 5.51 | — |
| Percent change at EOT of Cycle 6 | -76.3 ± 2.41 | — |
| Percent change at EOT of Cycle 7 | -83.0 ± NA | — |
| Percent change at EOT of Cycle 8 | -69.9 ± NA | — |
| Percent change at EOT of Cycle 9 | -70.5 ± NA | — |
Enteral autonomy (completely weaned off PS) was defined as the first visit where there is no use of PS for the 7 days prior to the visit and there is no prescribed PS at that visit, and the participants remains off PS for the remainder of the treatment period of that cycle. Number of participants who achieved enteral autonomy off PS volume at EOT of each cycle during teduglutide treatment were reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Participants | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| At EOT of Cycle 1 | 1 | 0 |
| At EOT of Cycle 2 | 1 | 0 |
| At EOT of Cycle 3 | 1 | 0 |
| At EOT of Cycle 4 | 1 | 1 |
| At EOT of Cycle 5 | 0 | — |
| At EOT of Cycle 6 | 0 | — |
| At EOT of Cycle 7 | 0 | — |
| At EOT of Cycle 8 | 0 | — |
| At EOT of Cycle 9 | 0 | — |
Days per week of diary PS was calculated as: Days per week of actual PS = (number of days with non-zero values for PS volume within the 7 days prior to the visit / number of days for which any PS intake data was recorded within the 7 days prior to the visit) \* 7. Change from baseline in days per week of diary PS usage at EOT of each cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Days/week | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Change at EOT of Cycle 1 | -1.2 ± 2.86 | 0.0 ± 0.00 |
| Change at EOT of Cycle 2 | -1.2 ± 2.86 | 0.0 ± NA |
| Change at EOT of Cycle 3 | -1.2 ± 2.86 | 0.0 ± NA |
| Change at EOT of Cycle 4 | -1.4 ± 3.13 | -7.0 ± NA |
| Change at EOT of Cycle 5 | 0.0 ± 0.00 | — |
| Change at EOT of Cycle 6 | 0.0 ± 0.00 | — |
| Change at EOT of Cycle 7 | 0.0 ± NA | — |
| Change at EOT of Cycle 8 | 0.0 ± NA | — |
| Change at EOT of Cycle 9 | 0.0 ± NA | — |
Change from baseline in days per week of prescribed PS usage at EOT of each cycle during teduglutide treatment was reported. Days per week of diary PS was calculated as: Days per week of actual PS = (number of days with non-zero values for PS volume within the 7 days prior to the visit / number of days for which any PS intake data was recorded within the 7 days prior to the visit) \* 7. Change from baseline in days Per week of prescribed PS usage at EOT of each cycle during teduglutide treatment was reported. Baseline refers to the baseline value of the core study (SHP633-302 \[NCT02980666\]).
| Days/week | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Change at EOT of Cycle 1 | -1.2 ± 2.86 | 0.0 ± 0.00 |
| Change at EOT of Cycle 2 | -1.2 ± 2.86 | 0.0 ± NA |
| Change at EOT of Cycle 3 | -16.7 ± 40.82 | 0.0 ± NA |
| Change at EOT of Cycle 4 | -20.0 ± 44.72 | -100.0 ± NA |
| Change at EOT of Cycle 5 | 0.0 ± 0.00 | — |
| Change at EOT of Cycle 6 | 0.0 ± 0.00 | — |
| Change at EOT of Cycle 7 | 0.0 ± NA | — |
| Change at EOT of Cycle 8 | 0.0 ± NA | — |
| Change at EOT of Cycle 9 | 0.0 ± NA | — |
Collected over From Baseline up to follow-up (up to 50 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Total Children (Aged: 1 to 15 Years) | 0/7 (0%) | 7/7 (100%) | 7/7 (100%) |
| Infants (Corrected Gestational Age: 4 to < 12 Months) | 0/2 (0%) | 2/2 (100%) | 2/2 (100%) |
| Event | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Device related infectionInfections and infestations | 4/7 | 1/2 |
| Pancreatitis acuteGastrointestinal disorders | 0/7 | 1/2 |
| Gastroenteritis adenovirusInfections and infestations | 0/7 | 1/2 |
| Otitis mediaInfections and infestations | 0/7 | 1/2 |
| Upper respiratory tract infectionInfections and infestations | 0/7 | 1/2 |
| Viral upper respiratory tract infectionInfections and infestations | 0/7 | 1/2 |
| SeizureNervous system disorders | 0/7 | 1/2 |
| Device breakageProduct Issues | 3/7 | 1/2 |
| Device damageProduct Issues | 2/7 | 0/2 |
| Colonic haematomaGastrointestinal disorders | 1/7 | 0/2 |
| Event | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) |
|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 4/7 | 1/2 |
| Injection site reactionGeneral disorders | 0/7 | 1/2 |
| ConjunctivitisInfections and infestations | 1/7 | 1/2 |
| Medical device site infectionInfections and infestations | 1/7 | 1/2 |
| Oral candidiasisInfections and infestations | 0/7 | 1/2 |
| Upper respiratory tract infectionInfections and infestations | 0/7 | 1/2 |
| Viral infectionInfections and infestations | 0/7 | 1/2 |
| Auricular haematomaInjury, poisoning and procedural complications | 0/7 | 1/2 |
| ContusionInjury, poisoning and procedural complications | 0/7 | 1/2 |
| Alanine aminotransferase increasedInvestigations | 0/7 | 1/2 |
The safety population included all enrolled participants in the study and who received at least one dose of teduglutide (in study SHP633-302 \[NCT02980666\] or SHP633-305 \[NCT03268811\]).
| Age, Customized(Participants) | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) | Total |
|---|---|---|---|
| Aged: 1 to 15 Years | 7 | 0 | 7 |
| Aged: 4 to < 12 Months | 0 | 2 | 2 |
| Sex: Female, Male(Participants) | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) | Total |
|---|---|---|---|
| Female | 1 | 1 | 2 |
| Male | 6 | 1 | 7 |
| Ethnicity (NIH/OMB)(Participants) | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 7 | 2 | 9 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Total Children (Aged: 1 to 15 Years) | Infants (Corrected Gestational Age: 4 to < 12 Months) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 7 | 2 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be re-identified (due to the limited number of study participants/study sites, ...).
Ran from Aug 2017 to primary completion in Nov 2021, 50 months.
Results were first posted in May 2022, 6 months after primary completion.
Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 50 months is above that.
Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Teduglutide